FDA
-
-
-
-
-
-
-
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
-
-
-
-
-
-
-
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
-
-
-
-
-
-
-
Radius Health (RDUS) and Menarini Report Subgroup Analysis from the Elacestrant Ohase 3 EMERALD Trial
-
-
-
-
-
-
-
Radius Health Update on Abaloparatide Transdermal System
-
-
-
-
-
-
-
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
-
-
-
-
-
-
-
Radius Provides Agenda for Today’s R&D Webcast
-
-
-
-
-
-
-
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
-
251,365 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All